Breakthrough drug targets ‘undruggable’ cancer, doubles survival in pancreatic cancer
TL;DR Summary
A large trial shows the experimental drug daraxonrasib inhibits all three RAS family proteins and nearly doubles survival in advanced pancreatic cancer (13.2 months vs 6.7 with chemotherapy), marking a breakthrough against previously undruggable targets and highlighting prospects for combination therapies and broader use in hard-to-treat tumors.
- Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments Nature
- Experimental pill promises new hope for deadly pancreatic cancer AP News
- This new drug could change how we treat one of the deadliest cancers PBS
- Daily pill can double survival time for world’s deadliest cancer, trial shows | Pancreas cancer The Guardian
- Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO 2026: A Game-Changer Oncology News Central
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
7 min
vs 8 min read
Condensed
97%
1,545 → 47 words
Want the full story? Read the original article
Read on Nature